Association of oncological response between the first-line chemotherapy and subsequent immune checkpoint inhibitors therapy in patients with unresectable or metastatic urothelial carcinoma

被引：1
|
作者：
Ozaki, Kai [1 ]
Hatakeyama, Shingo [2 ]
Hamaya, Tomoko [1 ]
Okita, Kazutaka [1 ]
Hashimoto, Yasuhiro [1 ]
Ohyama, Chikara [1 ,2 ]
机构：
[1] Hirosaki Univ, Grad Sch Med, Dept Urol, Hirosaki, Aomori, Japan
[2] Hirosaki Univ, Grad Sch Med, Dept Adv Blood Purificat Therapy, Hirosaki, Aomori, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2022年 / 29卷 / 04期
基金：
日本学术振兴会;
关键词：
D O I：
10.1111/iju.14778
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：362 / 364
页数：3
相关论文
共 50 条
  • [31] EFFECTIVENESS AND UTILIZATION OF FIRST-LINE IMMUNE CHECKPOINT INHIBITORS FOR PATIENTS WITH EXTRACRANIAL & INTRACRANIAL METASTATIC MELANOMA
    Lamba, Nayan
    Iorgulescu, Bryan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A265 - A266
  • [32] First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma
    Tsimafeyeu, Ilya
    Tjulandin, Sergei
    BJU INTERNATIONAL, 2019, 123 (04) : 563 - 565
  • [33] Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings.
    Lyou, Yung
    Grivas, Petros
    Rosenberg, Jonathan E.
    Hoffman-Censits, Jean H.
    Quinn, David, I
    Petrylak, Daniel Peter
    Galsky, Matt D.
    Vaishampayan, Ulka N.
    De Giorgi, Ugo
    Gupta, Sumati
    Burris, Howard A., III
    Rearden, Jessica
    Andresen, Corina
    Wang, Hao
    Daneshmand, Siamak
    Bajorin, Dean F.
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis
    Petrelli, Fausto
    Ferrara, Roberto
    Signorelli, Diego
    Ghidini, Antonio
    Proto, Claudia
    Roudi, Raheleh
    Sabet, Mehrdad N.
    Facelli, Sara
    Garassino, Marina C.
    Luciani, Andrea
    Roviello, Giandomenico
    IMMUNOTHERAPY, 2021, 13 (07) : 621 - 632
  • [35] Prognostic value of the CONUT score with immune checkpoint inhibitors as first-line therapy for metastatic malignant melanoma
    Horisaki, Ken
    Yoshikawa, Shusuke
    Mori, Shoichiro
    Omata, Wataru
    Tsutsumida, Arata
    Kiyohara, Yoshio
    JOURNAL OF DERMATOLOGY, 2025,
  • [36] Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma
    Yamagishi, Yoshiyuki
    Higuchi, Hajime
    Izumiya, Motoko
    Sakai, Gen
    Iizuka, Hideko
    Nakamura, Shoko
    Adachi, Masayuki
    Hozawa, Sigenari
    Takaishi, Hiromasa
    Hibi, Toshifumi
    JOURNAL OF GASTROENTEROLOGY, 2010, 45 (11) : 1146 - 1154
  • [37] Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma
    Yoshiyuki Yamagishi
    Hajime Higuchi
    Motoko Izumiya
    Gen Sakai
    Hideko Iizuka
    Shoko Nakamura
    Masayuki Adachi
    Sigenari Hozawa
    Hiromasa Takaishi
    Toshifumi Hibi
    Journal of Gastroenterology, 2010, 45 : 1146 - 1154
  • [38] Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts)
    Tzeng, Alice
    Diaz-Montero, C. Marcela
    Rayman, Patricia A.
    Kim, Jin Sub
    Pavicic, Paul G.
    Finke, James
    Barata, Pedro C.
    Lamenza, Marcelo
    Devonshire, Sarah
    Schach, Kim
    Emamekhoo, Hamid
    Ernstoff, Marc S.
    Hoimes, Christopher J.
    Rini, Brian I.
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ornstein, Moshe Chaim
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [39] Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study
    Agathe Vienne
    Laetitia Collet
    Thomas Chevalier
    Christian Borel
    Magalie Tardy
    Florence Huguet
    Sandrine Richard
    Sebastien Salas
    Esma Saada-Bouzid
    Jerome Fayette
    Amaury Daste
    BMC Cancer, 23
  • [40] Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study
    Vienne, Agathe
    Collet, Laetitia
    Chevalier, Thomas
    Borel, Christian
    Tardy, Magalie
    Huguet, Florence
    Richard, Sandrine
    Salas, Sebastien
    Saada-Bouzid, Esma
    Fayette, Jerome
    Daste, Amaury
    BMC CANCER, 2023, 23 (01)
12345